OpenClaim

Erdafitinib Side Effects

The most commonly reported side effects of erdafitinib include death, off label use, and diarrhoea, based on 1,159 FDA adverse event reports from 2018 to 2025. 3.0% of reports found the drug to be ineffective.

#1 Reported: DeathAll side effects ↓Top Co-Medication: Enfortumab-vedotin-ejfvDrug interactions ↓68% of Reports Are ElderlyDemographics ↓

Erdafitinib side effects

Percentages show how often each reaction appears relative to total reports for erdafitinib.

1
Death22.6%262
2
Off Label Use8.1%94
3
Diarrhoea7.2%83
4
Stomatitis5.3%61
5
Fatigue4.1%48
6
Onycholysis4.1%47
7
Nail Disorder4.1%47
8
Hyperphosphataemia3.7%43
9
Dry Mouth3.6%42
10
Disease Progression3.6%42
11
Dry Eye3.4%39
12
Mucosal Inflammation3.3%38
13
Drug Ineffective3.0%35
14
Decreased Appetite2.9%34
15
Nail Discolouration2.8%33

These are voluntary reports and do not establish that erdafitinib caused these reactions.

Report severity

73.2%Serious848 reports
20.4%Hospitalizations236 reports
28.4%Fatal329 reports

Seriousness is determined by the reporter, not by OpenClaim.

Erdafitinib drug interactions

Other drugs that appear in adverse event reports alongside erdafitinib. Drugs flagged as a suspected cause appear in the first column. Drugs taken at the same time but not suspected appear in the second.

Also suspected

1
Enfortumab-vedotin-ejfv1.6%18
2
Gemcitabine1.6%18
3
Paclitaxel1.5%17
4
Cisplatin1.5%17
5
Pembrolizumab1.4%16
6
Palbociclib0.9%11
7
Fulvestrant0.8%9
8
Gabapentin0.8%9
9
Pregabalin0.8%9
10
Hydromorphone-hydrochloride0.7%8
11
Docetaxel0.7%8
12
Dexamethasone0.6%7
13
Pomalidomide0.6%7
14
Ixazomib-citrate0.6%7
15
Osimertinib-mesylate0.5%6

Taken alongside

1
Acetaminophen2.5%29
2
Omeprazole2.1%24
3
Atorvastatin-calcium1.6%19
4
Apixaban1.6%18
5
Dexamethasone1.5%17
6
Metoprolol1.5%17
7
Pantoprazole-sodium1.5%17
8
Aspirin1.4%16
9
Gabapentin1.4%16
10
Sevelamer1.4%16
11
Loperamide-hydrochloride1.3%15
12
Furosemide1.1%13
13
Prednisone1.1%13
14
Amlodipine1.0%12
15
Metformin1.0%12

Co-occurrence in adverse event reports does not establish a drug interaction. Patients often take multiple medications, and these lists reflect prescribing patterns rather than causal relationships. Consult a healthcare provider about potential drug interactions.

Who reports erdafitinib side effects

30.2% of erdafitinib adverse event reports involve female patients and 51.1% involve male patients. The largest age group is elderly at 68%. These figures reflect who reports side effects, not underlying risk.

Sex

Female30.2%
Male51.1%
Unknown18.7%

Age group

< 20.0%
2–110.5%
12–172.1%
18–6429.5%
65+67.9%

What is erdafitinib used for

Conditions and purposes for which patients were taking erdafitinib when the adverse event was reported.

Accidental Exposure To ProductAdenocarcinoma GastricAdenocarcinoma PancreasAdenocarcinomaAstrocytomaBile Duct CancerBladder CancerBladder NeoplasmBladder Transitional Cell CarcinomaBrain NeoplasmBrain Neoplasm BenignBreast CancerBreast Cancer MetastaticBladder CancerBladder Neoplasm

Showing 15 of 114 indications

Erdafitinib brand names and reporting trend

Erdafitinib is sold under the brand name Erdafitinib.

Brand names

Erdafitinib759

Quarterly reports (2018–2025)

20182020202220242025

An upward trend reflects increased FAERS reporting overall, not necessarily increased risk.

Taking erdafitinib with another medication?

Ask OpenClaim about your specific drug combination. Get a sourced report using FDA data, drug labels, and medical literature.

Check my medications